Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHA:688016)
China · Delayed Price · Currency is CNY 96.95
-1.25 (-1.27%)
Feb 13, 2026, 3:00 PM CST
SHA:688016 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,248 | 1,203 | 1,187 | 896.5 | 684.63 | 465.06 |
Other Revenue | 3.67 | 3.67 | 0.01 | - | - | 5.19 |
| 1,252 | 1,206 | 1,187 | 896.5 | 684.63 | 470.25 | |
Revenue Growth (YoY) | -1.32% | 1.61% | 32.43% | 30.95% | 45.59% | 40.91% |
Cost of Revenue | 393.06 | 330.27 | 285.93 | 224.74 | 154 | 101.72 |
Gross Profit | 858.48 | 876.06 | 901.27 | 671.76 | 530.63 | 368.53 |
Selling, General & Admin | 323.84 | 250.25 | 185.19 | 150.02 | 103.81 | 77.95 |
Research & Development | 73.44 | 93.77 | 172.88 | 137.54 | 102.27 | 73.01 |
Other Operating Expenses | -7.68 | 9.59 | 9.85 | 8.3 | 5.32 | 2.8 |
Operating Expenses | 403.63 | 356.86 | 369.26 | 298.49 | 212.68 | 154.52 |
Operating Income | 454.85 | 519.2 | 532.01 | 373.27 | 317.95 | 214.02 |
Interest Expense | -2.31 | -1.65 | -1.82 | -2.09 | -1.77 | - |
Interest & Investment Income | 32 | 104.5 | 18.41 | 15.36 | 28.79 | 22.63 |
Currency Exchange Gain (Loss) | 1.59 | 1.59 | 1.19 | 2 | -0.44 | -0.9 |
Other Non Operating Income (Expenses) | 2.25 | -0.38 | -0.22 | -0.24 | -0.16 | -0.11 |
EBT Excluding Unusual Items | 488.38 | 623.26 | 549.58 | 388.29 | 344.38 | 235.63 |
Gain (Loss) on Sale of Assets | -0.7 | -0.7 | -0.1 | -0.23 | - | -0.04 |
Asset Writedown | -3.8 | - | - | - | - | - |
Other Unusual Items | 29.64 | 29.64 | 22.79 | 25.83 | 17.28 | 13.97 |
Pretax Income | 513.51 | 652.19 | 572.27 | 413.9 | 361.66 | 249.55 |
Income Tax Expense | 144.87 | 159.45 | 85.05 | 61.84 | 48.15 | 34.94 |
Earnings From Continuing Operations | 368.64 | 492.75 | 487.22 | 352.05 | 313.51 | 214.61 |
Minority Interest in Earnings | 9.18 | 9.35 | 5.21 | 4.83 | 2.34 | - |
Net Income | 377.82 | 502.1 | 492.43 | 356.88 | 315.86 | 214.61 |
Net Income to Common | 377.82 | 502.1 | 492.43 | 356.88 | 315.86 | 214.61 |
Net Income Growth | -42.52% | 1.96% | 37.98% | 12.99% | 47.17% | 51.40% |
Shares Outstanding (Basic) | 122 | 123 | 108 | 107 | 107 | 107 |
Shares Outstanding (Diluted) | 122 | 123 | 108 | 107 | 107 | 107 |
Shares Change (YoY) | 1.79% | 14.50% | 0.50% | 0.00% | -0.10% | 17.36% |
EPS (Basic) | 3.10 | 4.07 | 4.57 | 3.33 | 2.95 | 2.00 |
EPS (Diluted) | 3.10 | 4.07 | 4.57 | 3.33 | 2.95 | 2.00 |
EPS Growth | -43.54% | -10.95% | 37.30% | 12.99% | 47.32% | 29.01% |
Free Cash Flow | 56.94 | 160.95 | 368.05 | 39.78 | 210.67 | 191.22 |
Free Cash Flow Per Share | 0.47 | 1.30 | 3.42 | 0.37 | 1.97 | 1.78 |
Dividend Per Share | 1.662 | 2.012 | 2.013 | 1.544 | 1.409 | 0.604 |
Dividend Growth | -54.63% | -0.07% | 30.44% | 9.52% | 133.34% | 38.47% |
Gross Margin | 68.59% | 72.62% | 75.91% | 74.93% | 77.51% | 78.37% |
Operating Margin | 36.34% | 43.04% | 44.81% | 41.64% | 46.44% | 45.51% |
Profit Margin | 30.19% | 41.62% | 41.48% | 39.81% | 46.13% | 45.64% |
Free Cash Flow Margin | 4.55% | 13.34% | 31.00% | 4.44% | 30.77% | 40.66% |
EBITDA | 497.1 | 553.64 | 556.04 | 395.92 | 333.41 | 227.94 |
EBITDA Margin | 39.72% | 45.90% | 46.84% | 44.16% | 48.70% | 48.47% |
D&A For EBITDA | 42.25 | 34.44 | 24.03 | 22.65 | 15.46 | 13.92 |
EBIT | 454.85 | 519.2 | 532.01 | 373.27 | 317.95 | 214.02 |
EBIT Margin | 36.34% | 43.04% | 44.81% | 41.64% | 46.44% | 45.51% |
Effective Tax Rate | 28.21% | 24.45% | 14.86% | 14.94% | 13.31% | 14.00% |
Revenue as Reported | 1,252 | 1,206 | 1,187 | 896.5 | 684.63 | 470.25 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.